Cellular Imaging & Analysis 2008 Event by European Pharmaceutical Review

19-20 November, 2008, Basel, Switzerland.
Cellular Imaging and Analysis is becoming one of the hottest topics in the field of pharmaceutical research and development. Technical or diagnostic progress made almost hourly, this multi-disciplinary set of challenges and opportunities is proving one of the most profoundly effective in the history of science.

Cellular Imaging & Analysis 2008 will present papers at the forefront of thinking on the subject and is proud to feature some of the most pre-eminent scientists in the field.

Mr. Anthony Mitchell Davies, Director Trinity High Content Analysis Facility and Chair of Cellular Imaging & Analysis 2008, mentioned, "From the outset we have sought to produce a fresh, innovative, exciting and balanced agenda, covering many of the most important and challenging aspects of cellular imaging and analysis. For anyone involved in high content analysis, cell biology and related fields, it is expected that this meeting will provide a unique opportunity to interact with fellow scientists from a wide range of research areas. It is my belief that this meeting will become a point of convergence for many like minded scientists from both the industrial and academic domains."

For further information, and registration, please visit:
http://www.europeanpharmaceuticalreview.com/categories/
CellularImagingAnalysis2008

About European Pharmaceutical Review
European Pharmaceutical Review is the leading publication for information on technologies in drug discovery and manufacturing. Published bi-monthly, every issue offers a high level of technical and business contributions from the world's leading pharmaceutical companies and academic institutions, coupled with a variety of exciting new features including interviews, updates and profiles. For more information, visit www.europeanpharmaceuticalreview.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...